Carlos Doti: AstraZeneca’s Expanding Impact in Blood Cancer Care
Carlos Doti, VP US Medical Affairs of Oncology at AstraZeneca, shared a post on LinkedIn:
“ASH25 showcased AstraZeneca’s continued growth in hematology.
A decade ago, we presented one abstract. In 2025, we presented 65 abstracts, including:
- 15 oral presentations
- spanning 8 medicines
- 11 diseases
What makes this milestone meaningful isn’t just the science, but how our focus has evolved.
Our responsibility is clear: to help patients have the best quality of life.
As I hear directly from patients, what they want most is freedom from continuous treatment and the chance to return to what truly matters.
Thank you to Mary Caffrey for the opportunity to share these insights and discuss how AstraZeneca is advancing the future of blood cancer care. I encourage you to read the full piece in AJMC – The American Journal of Managed Care.”
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 8, 2026, 05:53Excellent PhD Defense by Roberta Cirsmaru on Gene Therapy for Hemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Jul 8, 2026, 05:48Riccardo Menandro: How Lipid Nanoparticles Are Shaping the Future of Rare Disease and Hemophilia Treatment
-
Jul 8, 2026, 05:39Daniel Victor Ortigoza: New Evidence from ATLANTIS-4D-CT on Apixaban and Subclinical Valve Thrombosis
-
Jul 8, 2026, 04:50Reza Bavarsad Shahripour: New AHA Guidance on Cryptogenic Stroke with Reduced Left Ventricular Function
-
Jul 7, 2026, 23:20Balaji Balagani: Exploring Pulmonary Embolism
-
Jul 7, 2026, 23:03Roxana González Mazarío: The Phenotype-Specific Cardiovascular Risks in AAV
-
Jul 7, 2026, 22:52Harry Spoelstra: LongC0VID Still has Zero Proven Treatments
-
Jul 7, 2026, 22:39Satya K. Morar: Acute Portal Vein Thrombosis as an Exceptionally Rare Complication of Liver Biopsy in CVID
-
Jul 7, 2026, 22:23Aravind Palraj: Antiphospholipid Syndrome is not Just ‘Start Warfarin and Follow INR’